Tag
A Sept 22, 2026 Annals of Oncology editorial from Stanford and University of South Carolina authors urges retiring 'negative' oncology names such as triple-negative breast cancer and non-small cell lung cancer in favour of molecularly defined entities, proposing hybrid transitional labels and biology-driven pathology reporting.
A recent study demonstrates that positive surgical margins in non-small cell lung cancer (NSCLC) do not vary significantly with resection type, supporting selective use of wedge resection without compromising oncologic outcomes.
This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly en
A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.
A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.
This review synthesizes evidence on the incidence, risk factors, and outcomes of secondary cancers in non-small cell lung cancer survivors post-definitive therapy, highlighting genetic predisposition as a key determinant distinct from recur
The Phase II PHAROS study demonstrates durable antitumor efficacy and manageable safety of encorafenib plus binimetinib in BRAF V600E-mutant metastatic NSCLC, with updated results showing the longest median overall survival reported for tar
In CHRYSALIS‑2 Cohort C, the amivantamab plus lazertinib combination produced a 52% ORR and durable responses (mDoR 14.1 months) in advanced NSCLC with atypical EGFR mutations, with higher activity in treatment‑naïve patients and an expecte
The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeut
The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety p
Co-administering midazolam with dexmedetomidine in elderly NSCLC patients undergoing lobectomy enhances hemodynamic stability and reduces perioperative stress response, potentially improving recovery outcomes without increasing adverse even
Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.
The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.
